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Abstract
Background: Antenatal corticosteroids have been proven to prevent adverse outcomes including respiratory
morbidities in preterm neonates before 34 weeks of gestation. Recently, it has been suggested that antenatal
corticosteroids may also be effective in singleton late preterm pregnancies, and guidelines recommend the use of
corticosteroids in singleton pregnant women who are at risk for late preterm birth. On the contrary, there is a
paucity of information regarding the effectiveness of corticosteroids in twin neonates with late preterm birth. This
study aims to determine the effectiveness of antenatal corticosteroids in late preterm twin neonates.
Methods: In this multicentre randomized controlled trial, women who are at risk for late preterm birth will be
enrolled at 34 0/7 to 36 5/7 weeks of gestation. The participants will be randomly assigned to receive antenatal
corticosteroids (betamethasone 12 mg, 3 mL intramuscularly [IM]) or placebo (normal saline 3 mL IM). The perinatal
outcomes will be compared between the two groups of cases. The primary outcome is severe respiratory
complications (the use of continuous positive airway pressure or high-flow nasal cannula for at least 12 h,
supplemental oxygen administration with a fraction of oxygen 0.3 or more for at least 24 h, mechanical ventilation,
or extracorporeal membranes oxygenation) or perinatal death within the first 72 h of delivery. The secondary
outcomes are neonatal mortality and/or other neonatal morbidities.
Discussion: This study will be the first randomized controlled trial that evaluates the effectiveness of antenatal
corticosteroids in late preterm twin neonates.
Trial registration: NCT03547791(ClinicalTrials.gov), first submitted date: March 29, 2018, first posted date: June 6,
2018 (retrospectively registered).
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Background
The number of multifetal pregnancies has recently been
increasing. Between 1980 and 2009, the frequency of
twin pregnancies in the United States increased by
three-fourths, from 18.9 to 33.3 per 1000 births, and this
phenomenon has been attributed to advancing maternal
age and increased use of assisted reproductive technique
[1]. Multifetal pregnancies are at higher risk for maternal
and neonatal complications compared with singleton
pregnancies, and preterm birth is one of the most im-
portant issues in twin pregnancies [2–5]. Indeed, the rate
of preterm birth in twin pregnancy is as high as 50%,
with most cases occurring in the late preterm period (34
0/7 to 36 6/7 weeks of gestation) [6, 7]. Late preterm
birth has recently emerged as a major health problem,
because late preterm neonates are at increased risk not
only for neonatal morbidities but also for childhood
complications as compared with term neonates [8–10].
For pregnant women at risk for early preterm delivery
(before 34 weeks of gestation), administration of ante-
natal corticosteroids is a standard treatment to reduce
perinatal mortality and morbidity, especially in terms of
respiratory complications [11–13]. Antenatal corticoste-
roids also can be beneficial for neonates at risk for late
preterm birth. Recently, a large randomized controlled
trial was conducted to investigate the effectiveness of
antenatal corticosteroids in singleton late preterm neo-
nates [14]. This study reported that administration of
betamethasone significantly reduced the rate of neonatal
respiratory complications in singleton late preterm neo-
nates. Based on this result, guidelines from the National
Institute for Health and Care Excellence (NICE), Society
for Maternal-Fetal Medicine (SMFM) and American
College of Obstetricians and Gynecologists (ACOG) rec-
ommend administration of betamethasone for pregnant
women at risk of late preterm birth in singleton gesta-
tion [15–17].
Some studies reported that antenatal corticosteroids
also improved neonatal outcomes in twin preterm births
before 34 weeks [13, 18, 19]. Based on these evidences
and effectiveness of corticosteroids in preterm singleton
pregnancy, ACOG recommends that one course of ante-
natal corticosteroids should also be used in multifetal
pregnant women who are at risk of early preterm birth
(before 33 6/7 weeks of gestation) [15, 20]. On the con-
trary, there is a paucity of information regarding the ef-
fectiveness of antenatal corticosteroids in twin late
preterm birth and the guidelines are not established in
this population [15].
The determination of the effectiveness of antenatal
corticosteroids in twin late preterm birth is a critical
issue with regard to several points. First, the neonatal
morbidities in twin preterm neonates may be different
from that in singleton preterm neonates [20]. Second,
the results of some retrospective studies on the effective-
ness of antenatal corticosteroids in preterm twin neo-
nates were conflicting. Some studies reported that the
effect of antenatal corticosteroids on neonatal outcomes
in twin pregnancy was comparable with that in singleton
pregnancy [13, 18, 19, 21]. However, there are disagree-
ments as to the effect of antenatal corticosteroids in twin
pregnancies [22, 23]. In addition, a recent report on the
use of a corticosteroid in twin late preterm birth showed
no reduction in respiratory morbidity [18]. Third, the
pharmacokinetics in women with twin pregnancy after
administration of betamethasone was different from that
in singleton pregnant women, probably resulting in a
different effectiveness of corticosteroids between single-
ton and twin pregnancies [24].
To determine this issue, we will evaluate the efficacy
of antenatal corticosteroids in twin pregnancies that are
at risk for late preterm birth.
Methods
Study design
In this multicentre, randomized, double-blind
placebo-controlled trial, women with a twin pregnancy
who are at risk for late preterm birth will be enrolled.
Figure 1 shows the model of the study design. After pro-
viding written informed consents, the women will be
randomly assigned to betamethasone or placebo admin-
istration. Except for the administration of antenatal cor-
ticosteroids or placebo, the participants will be treated
according to obstetric guidelines at the discretion of the
attending physician.
Study setting
This study will be conducted at obstetric departments of
two hospitals in South Korea, Seoul National University
Hospital and Cheil General Hospital and Women’s
Healthcare Centre. They are tertiary referral hospitals
and the number of twin delivery is approximately 300–
400/year in each centre.
Study population
Women with a twin pregnancy who are at risk for late
preterm delivery will be enrolled at 34 0/7 to 36 5/7
weeks of gestation. The risk for late preterm delivery in-
cludes preterm labour with cervical change, preterm
premature rupture of membranes, or maternal-foetal in-
dications that require preterm delivery because of mater-
nal (hypertensive disorder, maternal underlying diseases,
etc) or foetal causes (oligohydramnios, foetal growth re-
striction, etc). After screening for eligibility, information
regarding the study will be provided and written in-
formed consent will be obtained. Inclusion criteria and
exclusion criteria are shown in Table 1. Dropout criteria
include patient’s withdrawal of content, occurrence of
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Fig. 1 Study flow chart. PTL, preterm labour; PPROM, preterm premature rupture of membranes; M-F indication, maternal foetal indication;
IM, intramuscular
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Age > 20 years Gestational age before 34 weeks 0 days or after 36 weeks 6 days
Women with twin pregnancy at 34 weeks 0 days to
36 weeks 5 days of gestation
Lethal major foetal anomaly, foetal distress or foetal death in utero
At risk for preterm birth Expected to deliver within 12 h
preterm labour Advanced cervical dilatation (≥8 cm) in preterm labour
PPROM Active phase labour (cervical dilatation ≥4 cm) in PPROM
Maternal-foetal indications that need preterm delivery
Availability of written informed consent History of a previous administration of antenatal corticosteroid
within 1 week
Administration of systemic steroid for medical indications
Diagnosis of clinical chorioamnionitis
Contraindication of betamethasone administration
Preterm labour is defined as regular uterine contractions with or without the following symptoms; pelvic pressure, backache, increased vaginal discharge,
menstrual-like cramps, bleeding/show, cervical changes. Clinical chorioamnionitis is defined as fever > 37.8°C and the presence of two more of the following
conditions: uterine tenderness, foul-odoured vaginal discharge, maternal leucocytosis(> 1500), maternal tachycardia(> 100) or foetal tachycardia(> 160)
PPROM preterm premature rupture of memebrane
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severe adverse reaction, or clinical situation that does
not permit continuation of trial protocol at the discre-
tion of the investigators.
Random assignment method
Enrolled women will be randomly assigned in a 1:1 ratio
to antenatal corticosteroids (Group 1) or placebo (Group
2). The randomization will be done by a web-based
randomization system that is operated by the medical re-
search collaborating center of Seoul National University
Hospital. Unblinded researchers will be designated at the
beginning of this trial, including an unblinded pharma-
cist and unblinded investigators, and they will not par-
ticipate in the subsequent process of data management
and data analysis. The unblinded researchers will pre-
pare the antenatal corticosteroids or placebo according
to the treatment assignment. Neither the enrolled preg-
nant women nor the other investigators (except prede-
terminate unblinded researchers) will be aware of the
result of random assignment.
Sample size
The sample size was calculated to determine how many
neonates will be needed to detect a 30% reduction by
antenatal corticosteroids: 20% in the placebo group ver-
sus 14% in the antenatal corticosteroids group. We esti-
mated the risk of primary outcome in the placebo group
as 20%, with a correlation coefficient between co-twins
of 0.32, according to our retrospective twin cohort data.
We adopted a risk reduction rate of 30% (from 20 to
14%), according data in previous study [14]. Assuming
80% power, a type I error of 5%, and the ratio of 1:1 be-
tween placebo and antenatal corticosteroids, we deter-
mined we would require 1616 neonates (808 twin
pregnancies).
Intervention
The antenatal corticosteroids will be betamethasone so-
dium phosphate 5.2 mg (betamethasone 4.0 mg) in 1
ample (1 mL), produced by Dawon Parm (Korea). Both
betamethasone and placebo (normal saline) are
colourless liquids. The eligible participants for the in-
clusion and exclusion criteria will be randomized into
two groups: Group 1, antenatal corticosteroids group;
Group 2, placebo group. Group 1 consists of pregnant
women who will be administered intramuscular beta-
methasone 12 mg (3 mL) twice in a 24-h interval.
Group 2 will be administered the same amount (3
mL) of normal saline twice with the same interval.
Once the drug is determined by randomization, the
unblinded researchers will prepare and administer
betamethasone or placebo to participants.
Study outcomes
The data on obstetric and neonatal outcome will be
gathered. The primary outcome is severe respiratory
complications (the use of continuous positive airway
pressure or high-flow nasal cannula for at least 12 h,
supplemental oxygen administration with a fraction of
oxygen 0.3 or more for at least 24 h, mechanical ventila-
tion, or extracorporeal membranes oxygenation) or peri-
natal death within the first 72 h of delivery. Secondary
outcomes are neonatal mortality and/or other neonatal
morbidities (Table 2).
Safety assessment
The patients will be monitored for symptoms in terms
of adverse effects. The physicians will check the patients’
vital signs and the occurrence of adverse side effects
after injection. Symptoms such as nausea/vomiting, al-
lergic reaction, and local reaction at the injection site
will be reported. The administration of the study drug
can be interrupted in the occurrence of severe side ef-
fects, such as adrenal insufficiency, Cushing’s syndrome,
and infection. However, serious side effects after ante-
natal corticosteroids (betamethasone) were not reported
in previous studies in pregnant women [14, 25–27].
Analysis
The efficacy of betamethasone will be assessed by com-
paring the primary and secondary outcomes of each
group. Efficacy analysis will be conducted based on
intention-to-treat and per-protocol principle. Categorical
variables will be compared by the chi-square or Fish-
er’s exact test. For continuous variables, the
Mann-Whitney U test will be used. The analysis will
be performed by a generalized estimating equation to
consider the possibility of the familial correlation be-
tween the neonates from a single mother in twin
pregnancies [28]. A p value of less than 0.05 will be
considered significant, and relative risks and 95% con-
fidence intervals will be reported. All analyses will be
performed using IBM SPSS Statistics version 23 and
R version 3.5.0 (http://www.r-project.org).
Discussion
With this study, we intend to evaluate the efficacy of
antenatal betamethasone in late preterm delivery among
twin pregnancies. In clinical practice, antenatal cortico-
steroids are used to reduce neonatal morbidity and mor-
tality for preterm birth neonates (before 34 weeks of
gestation). Recently, the efficacy of the treatment has
also been proved for late preterm singleton neonates,
and the therapeutic targets of antenatal corticosteroids
has been expanded to late preterm neonates (34 0/7 to
36 6/7 weeks of gestation) as well as neonates born be-
fore 34 weeks of gestation.
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The efficacy of antenatal corticosteroids in twin neo-
nates with early preterm birth (before 34 weeks of gesta-
tion) has been demonstrated in several previous reports.
However, there has been no prospective randomized trial
on the efficacy of antenatal corticosteroids in twin preg-
nancies in late preterm birth. In this regard, research on
this issue is very crucial in clinical practice.
The results of this study are expected to have great
impact on several aspects.
First, the result of this study will provide evidence for
clinical guidelines of obstetric care in twin pregnancies.
To date, there are few obstetric studies on the effect-
iveness of antenatal corticosteroids in twin pregnan-
cies, and most of the existing studies have been
conducted in singleton pregnancies. Because of this,
guidelines about the administration of antenatal corti-
costeroids in twin pregnancy are based on evidences
from singleton pregnancy [15, 20].
Second, this study design has methodological strength.
This study is a double-blind, randomized controlled
study, which provides a high level of evidence. In
addition, the objectivity of evaluation variables is ex-
pected to yield objective results.
Third, the results of this study will have a significant
impact on improving national health and related pol-
icies. If the efficacy of antenatal corticosteroids in late
preterm neonates is demonstrated, the implementation
of guidelines on antenatal corticosteroids in late preterm
twin pregnancies will reduce adverse neonatal outcomes
and the subsequent burden due to hospitalization of ne-
onates. Otherwise, if the efficacy of antenatal corticoste-
roids is not proven, it may be the basis for avoiding
unnecessary treatment and adverse effects related to
corticosteroids.
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Table 2 Primary/Secondary outcomes
Primary outcome (within
72 h after delivery)
Secondary outcome
(before discharge)
Severe respiratory morbidities Mild respiratory morbidities
CPAP for ≥12 continuous hours CPAP for ≥2 continuous hours
High flow nasal cannula for ≥12
continuous hours
High flow nasal cannula for ≥2
continuous hours
Fraction of inspired oxygen of
≥0.3 for ≥24 continuous hours
Fraction of inspired oxygen of
≥0.3 for ≥2 continuous hours
Mechanical ventilation use Respiratory distress syndrome
ECMO use Transient tachypnoea of the
newborn
Stillbirth Apnoea

















CPAP continuous positive airway pressure, ECMO extracorporeal
membranes oxygenation
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